Analysts are on the Bearish side about Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) this week.

Investors sentiment decreased to 0.8 in 2018 Q3. Its down 0.24, from 1.04 in 2018Q2. It dived, as 47 investors sold Supernus Pharmaceuticals, Inc. shares while 90 reduced holdings. 35 funds opened positions while 74 raised stakes. 48.83 million shares or 3.12% less from 50.40 million shares in 2018Q2 were reported.
Fmr Limited Com invested in 0.01% or 2.37 million shares. Quantbot Techs Lp accumulated 2,252 shares or 0.01% of the stock. Prudential Fincl reported 126,000 shares. Ubs Asset Americas holds 177,171 shares or 0% of its portfolio. Regions holds 0% or 7,278 shares. Eventide Asset Mgmt Limited Liability Corp has 0.24% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Da Davidson holds 17,288 shares or 0.02% of its portfolio. Barclays Public Limited Com holds 80,943 shares or 0% of its portfolio. Essex Investment Co Ltd holds 0.38% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 63,754 shares. Kornitzer Management Ks holds 0.12% or 149,785 shares in its portfolio. State Of Alaska Department Of Revenue invested in 17,059 shares. Guggenheim Lc has 0.03% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 87,080 shares. Swiss National Bank & Trust reported 90,200 shares. Employees Retirement Association Of Colorado stated it has 7,732 shares. Century Incorporated accumulated 80,047 shares.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Ratings Coverage

Among 4 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Supernus Pharmaceuticals had 5 analyst reports since August 9, 2018 according to SRatingsIntel. FBR Capital maintained the stock with “Buy” rating in Monday, November 12 report. The stock has “Buy” rating by Jefferies on Thursday, August 9. Mizuho maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Monday, December 17 with “Buy” rating. Below is a list of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) latest ratings and price target changes.

17/12/2018 Broker: Mizuho Old Rating: Buy New Rating: Buy Old Target: $61 New Target: $63 Maintain
21/11/2018 Broker: SunTrust Rating: Buy New Target: $57.0000
12/11/2018 Broker: FBR Capital Old Rating: Buy New Rating: Buy Old Target: $68 New Target: $65 Maintain
18/09/2018 Broker: Mizuho Rating: Buy New Target: $61 Initiates Coverage On
09/08/2018 Broker: Jefferies Old Rating: Buy New Rating: Buy Old Target: $55 New Target: $58 Maintain

The stock decreased 1.94% or $0.73 during the last trading session, reaching $36.99. About 158,546 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 0.96% since January 14, 2018 and is uptrending. It has outperformed by 0.96% the S&P500.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $1.93 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 20.25 P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

More notable recent Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news were published by: Nasdaq.com which released: “SUPN Crosses Above Key Moving Average Level – Nasdaq” on December 03, 2018, also Globenewswire.com with their article: “Supernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with ADHD – GlobeNewswire” published on December 05, 2018, Seekingalpha.com published: “Supernus Pharma’s SPN-812 successful in two late-stage ADHD studies; investors unmoved, shares down 13% premarket – Seeking Alpha” on December 06, 2018. More interesting news about Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) were released by: Seekingalpha.com and their article: “Revisiting Supernus Pharmaceuticals – Seeking Alpha” published on September 27, 2018 as well as Globenewswire.com‘s news article titled: “Supernus to Present at Three November Healthcare Conferences – GlobeNewswire” with publication date: November 07, 2018.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.